Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
REVANCE THERAPEUTICS INC COM Analyst Ratings and Price Targets | NASDAQ:RVNC | Benzinga
REVANCE THERAPEUTICS INC COM Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for REVANCE THERAPEUTICS INC COM Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Mizuho
HC Wainwright & Co.
Piper Sandler
Stifel
1calculated from analyst ratings
Analyst Ratings for REVANCE THERAPEUTICS INC COM
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/17/2025 | Buy Now | — | Needham | Serge Belanger68% | — | Reiterates | Hold → Hold | Get Alert |
| 12/23/2024 | Buy Now | — | Barclays | Balaji Prasad52% | $7 → $3 | Maintains | Equal-Weight | Get Alert |
| 12/10/2024 | Buy Now | — | Mizuho | Vamil Divan76% | $6.66 → $3.1 | Maintains | Neutral | Get Alert |
| 11/08/2024 | Buy Now | — | Needham | Serge Belanger68% | — | Reiterates | → Hold | Get Alert |
| 11/08/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | $6.6 → $6.6 | Reiterates | Neutral → Neutral | Get Alert |
| 10/28/2024 | Buy Now | — | Needham | Serge Belanger68% | — | Reiterates | → Hold | Get Alert |
| 09/13/2024 | Buy Now | — | Barclays | Balaji Prasad52% | $10 → $7 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/13/2024 | Buy Now | — | Needham | Serge Belanger68% | — | Downgrade | Buy → Hold | Get Alert |
| 08/12/2024 | Buy Now | — | Guggenheim | Seamus Fernandez61% | — | Downgrade | Buy → Neutral | Get Alert |
| 08/12/2024 | Buy Now | — | William Blair | Tim Lugo34% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 08/09/2024 | Buy Now | — | Piper Sandler | David Amsellem68% | $11 → $6 | Maintains | Overweight | Get Alert |
| 08/09/2024 | Buy Now | — | Stifel | Annabel Samimy68% | $24 → $20 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | — | Needham | Serge Belanger68% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | $12 → $11 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | — | Goldman Sachs | Chris Shibutani54% | $9 → $8 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | — | Piper Sandler | David Amsellem68% | $20 → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2024 | Buy Now | — | Mizuho | Vamil Divan76% | $9 → $8 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | — | Needham | Serge Belanger68% | $18 → $12 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | — | Goldman Sachs | Chris Shibutani54% | $8 → $9 | Maintains | Neutral | Get Alert |
| 02/29/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | — | Piper Sandler | David Amsellem68% | $42 → $20 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | — | Needham | Serge Belanger68% | $20 → $18 | Maintains | Buy | Get Alert |
| 02/23/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | $15 → $12 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | — | Barclays | Balaji Prasad52% | $35 → $10 | Maintains | Overweight | Get Alert |
| 01/29/2024 | Buy Now | — | Mizuho | Vamil Divan76% | $16 → $9 | Downgrade | Buy → Neutral | Get Alert |
| 01/09/2024 | Buy Now | — | Needham | Serge Belanger68% | $25 → $20 | Maintains | Buy | Get Alert |
| 01/09/2024 | Buy Now | — | Goldman Sachs | Chris Shibutani54% | $30 → $8 | Downgrade | Buy → Neutral | Get Alert |
| 11/22/2023 | Buy Now | — | Mizuho | Uy Ear63% | $35 → $16 | Maintains | Buy | Get Alert |
| 11/09/2023 | Buy Now | — | Piper Sandler | David Amsellem68% | $44 → $42 | Maintains | Overweight | Get Alert |
| 11/09/2023 | Buy Now | — | Needham | Serge Belanger68% | $35 → $25 | Maintains | Buy | Get Alert |
| 11/06/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | $41 → $15 | Maintains | Buy | Get Alert |
| 10/23/2023 | Buy Now | — | Barclays | Balaji Prasad52% | $40 → $35 | Maintains | Overweight | Get Alert |
| 10/11/2023 | Buy Now | — | Morgan Stanley | Terence Flynn66% | $25 → $12 | Maintains | Equal-Weight | Get Alert |
| 09/21/2023 | Buy Now | — | Goldman Sachs | Chris Shibutani54% | $38 → $33 | Maintains | Buy | Get Alert |
| 09/20/2023 | Buy Now | — | Piper Sandler | David Amsellem68% | $50 → $44 | Maintains | Overweight | Get Alert |
| 09/20/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | → $41 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2023 | Buy Now | — | Needham | Serge Belanger68% | $40 → $35 | Maintains | Buy | Get Alert |
| 08/16/2023 | Buy Now | — | Exane BNP Paribas | Navann Ty69% | → $20 | Upgrade | Underperform → Neutral | Get Alert |
| 08/15/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | → $41 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | — | Needham | Serge Belanger68% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | — | Morgan Stanley | Terence Flynn66% | $26 → $25 | Maintains | Equal-Weight | Get Alert |
| 08/09/2023 | Buy Now | — | Needham | Serge Belanger68% | $44 → $40 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | $48 → $41 | Maintains | Buy | Get Alert |
| 07/11/2023 | Buy Now | — | Morgan Stanley | Terence Flynn66% | $26 → $26 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/07/2023 | Buy Now | — | Mizuho | Vamil Divan76% | $33 → $35 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | — | Needham | Serge Belanger68% | $40 → $44 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | $42 → $48 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | — | Needham | Serge Belanger68% | → $40 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | → $42 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | — | Barclays | Balaji Prasad52% | $37 → $40 | Maintains | Overweight | Get Alert |
| 03/01/2023 | Buy Now | — | Needham | Serge Belanger68% | $38 → $40 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | → $42 | Reiterates | → Buy | Get Alert |
| 01/31/2023 | Buy Now | — | Piper Sandler | David Amsellem68% | $29 → $40 | Maintains | Overweight | Get Alert |
| 01/26/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | $29 → $42 | Maintains | Buy | Get Alert |
| 01/24/2023 | Buy Now | — | Morgan Stanley | Terence Flynn66% | $25 → $26 | Maintains | Equal-Weight | Get Alert |
| 01/10/2023 | Buy Now | — | Needham | Serge Belanger68% | $35 → $38 | Maintains | Buy | Get Alert |
| 11/16/2022 | Buy Now | — | Barclays | Balaji Prasad52% | $35 → $37 | Maintains | Overweight | Get Alert |
| 11/09/2022 | Buy Now | — | Morgan Stanley | Terence Flynn66% | $27 → $25 | Maintains | Equal-Weight | Get Alert |
| 10/11/2022 | Buy Now | — | Morgan Stanley | Terence Flynn66% | → $27 | Initiates | → Equal-Weight | Get Alert |
| 09/22/2022 | Buy Now | — | Goldman Sachs | Chris Shibutani54% | → $33 | Initiates | → Buy | Get Alert |
| 09/09/2022 | Buy Now | — | Mizuho | Vamil Divan76% | $26 → $30 | Maintains | Buy | Get Alert |
| 09/09/2022 | Buy Now | — | Barclays | Balaji Prasad52% | $22 → $35 | Maintains | Overweight | Get Alert |
| 09/09/2022 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao53% | $25 → $29 | Maintains | Buy | Get Alert |
| 09/09/2022 | Buy Now | — | Needham | Serge Belanger68% | $25 → $35 | Maintains | Buy | Get Alert |
| 08/25/2022 | Buy Now | — | Wells Fargo | Jacob Hughes52% | $17 → $24 | Maintains | Equal-Weight | Get Alert |
| 05/11/2022 | Buy Now | — | Mizuho | Vamil Divan76% | → $26 | Maintains | Buy | Get Alert |
FAQ
What is the target price for REVANCE THERAPEUTICS INC COM (RVNC) stock?
The latest price target for REVANCE THERAPEUTICS INC COM (NASDAQ:RVNC) was reported by Needham on January 17, 2025. The analyst firm set a price target for $0.00 expecting RVNC to fall to within 12 months (a possible NaN% downside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for REVANCE THERAPEUTICS INC COM (RVNC)?
The latest analyst rating for REVANCE THERAPEUTICS INC COM (NASDAQ:RVNC) was provided by Needham, and REVANCE THERAPEUTICS INC COM reiterated their hold rating.
When was the last upgrade for REVANCE THERAPEUTICS INC COM (RVNC)?
The last upgrade for REVANCE THERAPEUTICS INC COM happened on August 16, 2023 when Exane BNP Paribas raised their price target to $20. Exane BNP Paribas previously had an underperform for REVANCE THERAPEUTICS INC COM.
When was the last downgrade for REVANCE THERAPEUTICS INC COM (RVNC)?
The last downgrade for REVANCE THERAPEUTICS INC COM happened on September 13, 2024 when Barclays changed their price target from $10 to $7 for REVANCE THERAPEUTICS INC COM.
When is the next analyst rating going to be posted or updated for REVANCE THERAPEUTICS INC COM (RVNC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of REVANCE THERAPEUTICS INC COM, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for REVANCE THERAPEUTICS INC COM was filed on January 17, 2025 so you should expect the next rating to be made available sometime around January 17, 2026.
Is the Analyst Rating REVANCE THERAPEUTICS INC COM (RVNC) correct?
While ratings are subjective and will change, the latest REVANCE THERAPEUTICS INC COM (RVNC) rating was a reiterated with a price target of $0.00 to $0.00. The current price REVANCE THERAPEUTICS INC COM (RVNC) is trading at is $undefined, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.